Prognostic-disability Biomarkers in Multiple Sclerosis: Review of the Literature from the Last Five Years
Journal Title: UNKNOWN - Year 2018, Vol 24, Issue 3
Abstract
With the advent of new agents in the treatment of multiple sclerosis, new treatment modalities have emerged (escalation-induction therapy) and the increased efficacy of the drugs has led to increased drug-related risks. The risk/benefit balance has become more carefully assessed. The increased need for reliable markers to predict prognosis-disability has also led to an increase in research conducted in this area. In this short review, studies published between 2012-2017, especially those related to prognosis and disability, were compiled.
Authors and Affiliations
Nefati Kıylıoğlu
Keywords
Related Articles
- EP ID EP392434
- DOI 10.4274/tnd.79836
- Views 72
- Downloads 0
Recurrence of Sydenham’s Chorea
.
A Treatable Reason of Myopathy: Hypothyroidism
.
Adjunctive Everolimus Therapy for Treatment-resistant Focal-onset Seizures Associated with Tuberous Sclerosis: A Phase 3, Randomised, Double-blind, Placebo-controlled Study
.
A New Treatment Option for Amyotrophic Lateral Sclerosis: Edaravone
.
Ischemic Stroke Subtypes and Migraine with Visual Aura
.